The purpose of our study was to develop a therapeutic target that can reduce Ab and Drp1 levels, and also can inhibit abnormal interactions between Ab and Drp1 in AD neurons. To achieve this objective, we designed various compounds and their 3-dimensional molecular structures were introduced into Ab and Drp1 complex and identified their inhibitory properties against Ab-Drp1 interaction. Among all, DDQ was selected for further investigation because of 1) its best docking score and 2) its binding capability at interacting sites of Drp1 and Ab complex. We synthesized DDQ using retro-synthesis and analyzed its structure spectrally. Using biochemical, molecular biology, immunostaining and transmission electron microscopy (TEM) methods, we studied DDQ's beneficial effects in AD neurons. We measured the levels of Ab and Drp1, Ab and Drp1 interaction, mRNA and protein levels of mitochondrial dynamics, biogenesis and synaptic genes, mitochondrial function and cell viability and mitochondrial number in DDQ-treated and untreated AD neurons. Our qRT-PCR and immunoblotting analysis revealed that reduced levels of mitochondrial fission and increased fusion, biogenesis and synaptic genes in DDQ-treated AD neurons. Our immunoblotting and immunostaining analyses revealed that Ab and Drp1 levels were reduced in DDQ-treated AD neurons. Interaction between Ab and Drp1 is reduced in DDQ-treated AD neurons. Ab42 levels were significantly reduced in DDQ-treated mutant APP Swe/Ind cells. Mitochondrial number is significantly reduced and mitochondrial length is significantly increased. Mitochondrial function and cell viability were maintained in AD neurons treated with DDQ. These observations indicate that DDQ reduces excessive mitochondrial fragmentation, enhances fusion,
Introduction
The World Alzheimer's Report estimated that in 2015, 47.5 million people had AD-related dementia worldwide, and these numbers were expected to rise to 75.6 million by 2030 and to 131.5 million by 2050. Over 9.9 million new cases of AD-related dementia are diagnosed every year worldwide, which translates to 1 new case every 3.2 s. Dementia has a huge economic impact on our society, on the persons with dementia, and on their families and caretakers. The estimated total healthcare cost of dementia worldwide in 2015 was estimated at $818 billion, and the World Alzheimer's Report foresees dementia as a trillion-dollar disease by 2018 (1) .
While scientists are trying to determine the causes of AD, they have pinpointed several cellular changes that increase a person's risk for developing it, including synaptic loss and dysfunction, Ab production and accumulation, inflammatory responses, phosphorylated tau formation and accumulation, cell cycle deregulation, and hormonal imbalance (2) (3) (4) (5) (6) (7) (8) (9) . Aging is the number one risk factor for AD. AD pathogenesis has been linked to oxidative DNA damage. In mammals, including humans, an accumulation of oxidative DNA damage in different tissues, including brain tissue, has been found in aging persons. In AD, Ab-induced synaptic dysfunction is a complicated process involving multiple pathways, components, and biological events, such as oxidative stress, kinase activation, and protein interactions. These complexities lead to the formation and accumulation of Ab and phosphorylated tau, mitochondrial dysfunction, and ultimately neuronal death. Despite the numbers of clinical trials conducted to identify drug targets that may reduce mutant protein toxicity in AD, such molecules remain unidentified. Recent research established that synaptic damage and mitochondrial dysfunction are early events in AD pathogenesis (5, 7) . Mitochondrial dysfunction is mainly due to the abnormal interaction of mitochondrial fission protein, Drp1 with Ab, and Drp1 with phosphorylated tau (10) (11) (12) (13) (14) .
Extracellular canonical localization of Ab has been identified in different subcellular compartments, including the endoplasmic reticulum; the Golgi apparatus (or the trans-Golgi network); early, late, and recycling endosomes; and the lysosome, where the Ab are generated (15) . In studies of postmortem brains from both AD patients and mouse models of AD, Ab has also been found in mitochondria, and research from different independent research groups have clearly established that Ab progressively accumulates in the mitochondria (5, (16) (17) (18) (19) (20) (21) (22) . Ab has been found to induce mitochondrial dysfunction via different mechanisms. Ab is taken up by mitochondria via the translocase of the outer membrane complex and is imported into the inner membrane (23) ; Ab alters the enzyme activity of the respiratory chain complexes I, II, and IV, Ab affects mitochondrial dynamics by an impaired balance of fission and fusion (15) ; Ab impairs mitochondrial permeability transition pore gating via the interaction of Ab with VDAC1 (12) ; Ab induces decreased mitochondrial respiration Ab affects new mitochondrial biogenesis and Ab increases reactive oxygen species (ROS) generation (5, (23) (24) (25) (26) (27) .
Recent studies from our lab (10, (28) (29) and others (30-32) have shown that Drp1, which maintains and remodels mammalian mitochondria, interacts with Ab and phosphorylates tau (11) (12) , leading to excessive mitochondrial fragmentation, impaired axonal transport of mitochondria, and ultimately, neuronal damage and cognitive decline. Drp1 is critical for mitochondrial division, maintenance of mitochondrial network, size, shape and distribution in mammalian neurons (33) (34) (35) .
Structurally, the human Drp1 has been found to have several splice variants: variant 1 consists of 736 amino acids; in variant 2, exon 15 is spliced out; in variant 3, exons 15 and 16 are spliced out and have a total of 699 amino acids; variant 4 has 725 amino acids; variant 5, 710 amino acids; and variant 6, 749 amino acids (34) (35) . Drp1 contains a highly conserved GTPase and is involved in various cellular functions. Similar to the human Drp1, the mouse Drp1 has been found in multiple variants: variant 1 consists of 712 amino acids; in variant 2, exon 3 is spliced out; and in variant 3, exons 15 and 16 are spliced out. Recent research findings suggest that Drp1 is involved in mitochondrial division, mitochondrial distribution, peroxisomal fragmentation, phosphorylation, SUMOlyation, and ubiquitination.
Studies of Drp1 in mammalian cells suggest that the normal expression of Drp1 is critical for normal mitochondrial dynamics and normal mitochondrial distribution and dendritic morphology in neurons (33) . In AD and other neurodegenerative diseases, Drp1 levels are altered via the interaction of Drp1 with mutant proteins such as Ab and mutant huntingtin, leading to abnormal mitochondrial dynamics (increased fission and reduced fusion), in some cases with perinuclear clusters of mitochondria and disruption of inter-mitochondrial connectivity (31) (32) .
Recent evidence from studies conducted by our lab suggests that mutant AD proteins, Ab, and phosphorylated tau interact with Drp1, which induces excessive mitochondrial fragmentation, impaired mitochondrial dynamics, mitochondrial dysfunction, and synaptic damage in AD neurons (10) (11) . These abnormal interactions are believed to be age-and diseaseprogression dependent, indicating that the interaction between aging and disease progression may play key roles in AD pathogenesis and development. Increasing evidence (5, (36) (37) (38) , suggests that in AD, the accumulation of Ab in synapses and synaptic mitochondria causes synaptic mitochondrial failure and synaptic degeneration.
Development of drugs capable of targeting underlying mechanisms of disease pathogenesis is needed in order to slow AD progression. The major focus of the research effort is to develop a drug that can target the toxicity involved in these interactions in order to prevent mitochondrial dysfunction and synaptic damage in AD progression. Currently, there are no selective drug targets capable of preventing and/or inhibiting the abnormal interactions between Ab and Drp1, and of delaying the agedependent AD process. Our lab has been conducting studies, the goal of which is to develop drug molecules or molecular inhibitors capable of inhibiting or reducing abnormal interactions between Ab and Drp1 and of protecting neurons from multiple injuries caused by Ab and Drp1 interactions and Ab-and Drp1-induced mitochondrial and synaptic toxicities. Consequently, we designed 82 molecular structures that are capable to: 1) delay aging and prevent/delay age-related insults in neurons, 2) protect neurons from oxidative insults, 3) inhibit abnormal protein-protein interactions and protect neurons from mutant protein(s)-induced toxicities, and 4) enhance cell survival. These structures were designed based on the existing drug molecules such MitoQ, Mdivi1, and SS31 (39) (40) (41) (42) (43) . Dopamine, neurotransmitter and a precursor of other substances including epinephrine is selected as a base moiety to design these structures.
Dopamine is a neurotransmitter that occurs naturally in the body. It is formed by the removal of carboxyl group from L-Dopa (3, 4-Dihydroxyphenethylamine). The IUPAC name for dopamine is 4-(2-Aminoethyle) benzene-1, 2-diol. It helps control the brain's reward and pleasure centers. Dopamine deficiency causes Parkinson's disease, and people with low dopamine activity may be more prone to addiction. Dopamine injection (intropin) is used to treat certain conditions, such as low pressure, that occur when you are in shock, which may be caused by heart attack, trauma, surgery, heart failure, kidney failure, and other serious medical conditions. But some times over dosage may lead to allergic reactions such as hives, difficult breathing, and swelling of face, lips, tongue, or throat (44) .
Keeping the importance of dopamine and based on the molecular structures of existing drug molecules, we designed various dopamine derived structures to treat against AD causing pathways. Subsequently, we conducted molecular docking analysis for designed 82 scaffold structures. We selected the best molecule, out of the 82 that is DDQ -which exhibited the best binding energy values and obstructing the active binding interacting sites of Ab and Drp1 (45) . In the current study, using AD neurons, we sought to determine 1) the production of Ab and Drp1 levels, 2) Ab and Drp1 interaction, 3) mRNA and protein levels of mitochondrial dynamics, biogenesis and synaptic genes, 4) mitochondrial function and cell viability and 5) mitochondrial number and morphology in AD neurons treated and untreated with DDQ.
Results

Molecular docking results
We prepared a protein complex of Ab and Drp1 by retrieving the crystal structures of Ab (PDB ID: 1ba4) and dynamin-1-like protein (PDB ID: 4h1u) from a protein data bank. In Ab and Drp1 complex, Ser8, Leu34, Gly120, Gly25 of Ab are interacting with Interaction of Drp1 and designed drug molecules. We designed 82 molecules based on existing mitochondrial division inhibiting drug molecules in AD and subjected to molecular docking studies. We prepared Ab and Drp1 complex and introduced these molecular structures into this complex. Few of these molecule showed better docking score compared to existed drug molecules. Amongst DDQ is only involved in the prevention of Ab-Drp1 interaction by interacting at the active site such as ser8 and Leu34 of Ab and ASN16 Glu16 of Drp1. And also DDQ showed better binding score (-10.8462) than existed drug molecules. DDQ is readily stopping the Drp1 before forming the complex. DDQ exhibited binding interaction at Arg225 (C ¼ O!O-P) and phenyl part of DDQ is also showing one arene cationic interaction at Arg225. Hence, among all designed molecules we selected only DDQ for our further steps.
ASN98, ILU22, ASN12, Glu22 of Drp1 respectively; we predicted these sites as active interacting sites of Ab and Drp1 complex. Designed molecular structures were introduced into Ab and Drp1 complex (Fig. 1 ) in order to identify the interactions of ligands in the complex and identify their inhibitory properties against Ab-Drp1 interaction. Few molecules showed good binding score against this complex. Particularly, DDQ only interacted at specific interacting sites in the Ab-Drp1 complex and exhibited the best docking capability and received the best docking score than all other molecules. Correspondingly, DDQ is obstructing these Ab and Drp1 bindings by direct interactions at active sites such as ser8 and Leu34 of Ab and ASN16 Glu16 of Drp1. DDQ is readily bound with Drp1 independently before forming a complex. Therefore, we selected DDQ as a selective target to treat against AD neuronal cells. We synthesized DDQ by following protocol.
Synthesis of diethyl (3,4-dihydroxyphenethylamino) (quinolin-4-yl)methylphosphonate (DDQ)
To synthesize DDQ, we followed two-step Pudovik reaction. In the first step 4-(2-(quinolin-4-ylmethyleneamino)ethyl)benzene-1,2-diol was prepared by stirring 4-(2-aminoethyl)benzene-1,2-diol with quinoline-4-carbaldehyde at reflection temp 80 C of THF (Fig. 2) . We isolated the intermediates and 4-(2-(quinolin-4-ylmethyleneamino)ethyl)benzene-1,2-diol is selected for the second step reaction. In the second step, Dethylphosphite (DEP) was added to the solution of (Z)-4-(2-(quinolin-4-ylmethyleneamino)ethyl)benzene-1,2-diolin in drop-wise fashion, at room temperature in the presence of the SiO 2 ÁOSO 3 H catalyst. The reaction mixture was stirred continuously for 4 h at 65 C. The reaction between DEP and Z)-4-(2-(quinolin-4-ylmethyleneamino)ethyl)benzene-1,2-diol was monitored by thin-layer chromatography, using silica gel as the adsorbent and a mixture of ethyl acetate and hexane (1:2) as the eluent. After the reaction was complete, the mixture was quenched with water, and four samples of ethyl acetate (each at 10 mL) were then extracted. The samples were concentrated, using reduced pressure. The resulting mixture was purified by column chromatography, using a 100-200 mesh silica gel as the adsorbent and a mixture of ethyl acetate and hexane (1:4) as the eluent, to derive the pure DDQ.
Spectral data for diethyl (3,4- (47) (48) . Based on the molecular docking results, synthesized DDQ is forwarded to screen its reducing effect of Ab and Drp1 levels and to determine its inhibiting capacity against Ab and Drp1 complex formation. So that, we treated DDQ in human neuroblastoma (SHSY5Y) cells as shown in Figure 3 . These treated cells were used to quantify the effect of DDQ on gene expression and protein levels of synaptic, AD-related, and mitochondrialrelated genes. We determined the Ab and Drp1 interaction inhibitory property of DDQ and also quantified the number of mitochondria in the treated cells.
mRNA levels of mitochondrial dynamics, mitochondrial biogenesis and synaptic genes Using the reagent TriZol (Invitrogen), we isolated total RNA from all DDQ-treated and untreated cells. mRNA levels of mitochondrial dynamic (Drp1, Fis1, Mfn1 and Mfn2), mitochondrial biogenesis genes (PGC1a, Nrf1, Nrf2 and TFAM) and synaptic genes (PSD95, synaptophysin, synapsin 1, synapsin 2, synaptobrevin 1, synaptobrevin 2, synaptopodin, and GAP43) were measured by using Sybr-Green chemistry-based quantitative real time RT-PCR. As shown in Table 2 , in Ab-treated cells Drp1 and in Fis1 (mitochondrial fission genes) expression levels were significantly increased by 2.2 fold (P ¼ 0.004), and 1.7 fold (P ¼ 0.003) respectively, compared to untreated cells. In contrast, mRNA expression levels of mitochondrial fusion genes were significantly decreased (Mfn1 by 2.3 fold (P ¼ 0.005) and Mfn2 by 2.6 fold (P ¼ 0.001)) in Ab-treated cells relative to untreated cells. This indicates the presence of abnormal mitochondrial dynamics in cells treated with Ab. Drp1 (2.2 fold decrease, P ¼ 0.01 in DDQtreated cells) and Fis1 (4.4 fold decrease, P ¼ 0.001) mRNA levels were significantly decreased and fusion genes, Mfn1 (1.7 fold P ¼ 0.02) and Mfn2 (2.3 fold P ¼ 0.002) mRNA levels are increased in DDQ-treated cells relative to untreated cells. mRNA changes were significantly reduced for fission genes Drp1 and Fis1, and increased for fusion genes Mfn1 and Mfn2 in cells incubated with Ab and then treated with DDQ relative to untreated cells. Similarly, cells pretreated with DDQ and incubated with Ab relative to untreated cells, mRNA levels were unchanged for fission genes Drp1 and Fis1, and fusion genes Mfn1 and Mfn2.
Mitochondrial biogenesis genes (PGC1a, Nrf1, Nrf2 and TFAM) expressions were significantly decreased in Ab effected neuronal cells and healthy increase in DDQ-treated cells relative to untreated cells. Biogenesis genes mRNA expression of Ab effected neuronal cells was decreased as PGC1a by 4.4 fold (P ¼ 0.001), Nrf1 by 4.1 fold (P ¼ 0.004), Nrf2 by 2.8 fold (P ¼ 0.01) and TFAM by 4.6 fold (P ¼ 0.002)) relative to untreated cells. Biogenesis genes mRNA levels in DDQ-treated cells relative were significantly increased as PGC1a (1.5 fold decrease, P ¼ 0.02), Nrf1 by 1.9 fold (P ¼ 0.01), Nrf2 by 2.7 fold (P ¼ 0.01) and TFAM by 1.7 fold (P ¼ 0.02) relative to untreated cells (Table 2 ). These observations indicate that DDQ increases mitochondrial biogenesis activity. Mitochondrial biogenesis genes PGC1a (2.5 fold P ¼ 0.01), Nrf1 (2.6 fold P ¼ 0.003), Nrf2 (2.1 fold P ¼ 0.03) and TFAM (2.3 fold P ¼ 0.01) levels were significantly increased in cells incubated with Ab followed by treated with DDQ relative to Ab-treated cells. DDQ pretreated followed by Ab-incubated cells exhibited increased of mRNA levels for biogenesis genes (PGC1a (3.9 fold P ¼ 0.002), Nrf1 (4.9 fold P ¼ 0.0003), Nrf2 (2.6 P ¼ 0.01) and TFAM (3.2 P ¼ 0.002)) relative to Ab-treated cells. These results suggest that DDQ pretreatment prevented Ab induced biogenesis toxicity.
In cells treated with Ab compared with untreated cells, mRNA expression levels were decreased for synaptophysin by 3.7 fold (P ¼ 0.0002), PSD95 by 2.5 fold (P ¼ 0.004), synapsin1 by 1.9 (P ¼ 0.02), synapsin2 by 1.4 (P ¼ 0.04), synaptobrevin1 by 2.4 (P ¼ 0.003), synaptobrevin2 by 2.3 (P ¼ 0.01), synaptopodin by 2.3 (P ¼ 0.001) and GAP43 by 1.9 (P ¼ 0.001) indicating that Ab reduces synaptic activity. mRNA levels were significantly increased for synaptophysin by 1.4 fold (P ¼ 0.04), PSD95 by 1.4 (P ¼ 0.03), Synapsin2 by 1.7 (P ¼ 0.01), synaptobrevin2 by 1.3, and GAP43 by 1.2 fold in DDQ-treated cells relative to untreated cells. These observations indicate that DDQ boosts synaptic activity in healthy cells. In cells incubated with Ab and then treated with DDQ relative to untreated cells, mRNA levels were increased. These observations indicate that DDQ rescued synaptic activity from Ab induced toxicity. In cells pretreated with DDQ and incubated with Ab relative to Ab cells, mRNA levels were increased for synaptic mitochondrial biogenesis and mitochondrial fusion genes, indicating that DDQ enhances synaptic and mitochondrial fusion activities.
In cells incubated with Ab and then treated with DDQ and pretreated with DDQ and incubated with Ab relative to Abtreated cells, the fold change of mitochondrial fission genes (Drp1 and Fis1) were down-regulated and mitochondrial fusion genes (Mfn1 and Mfn2) were significantly upregulated. Similarly, 
Immunoblotting analysis
To determine the effects of Ab on mitochondrial proteins and the useful effects of DDQ at the protein level, we quantified mitochondrial proteins in five independent treatments of cells with Ab, DDQ, AbþDDQ and DDQ þ Ab.
Comparison with untreated cells. In SHSY5Y cells treated with Ab compared with untreated SHSY5Y cells, significantly increased protein levels were found for Drp1 (P ¼ 0.01) and Fis1 (P ¼ 0.01) ( Fig. 4A and C) . In contrast, decreased levels of mitochondrial fusion proteins, Mfn1 (P ¼ 0.002) and Mfn2 (P ¼ 0.004) were found in cells incubated with Ab compared with untreated cells. Synaptophysin (P ¼ 0.001) and PSD95 (P ¼ 0.01) levels were significantly reduced in Ab-incubated cells relative to untreated cells ( Fig. 4A and C) .
Mitochondrial fission proteins, Drp1 (P ¼ 0.03) and Fis1 were significantly reduced and fusion protein Mfn2 P ¼ 0.004 was significantly increased in DDQ-treated cells relative to untreated cells ( Fig. 4A and C) . Mitochondrial biogenesis protein levels were significantly increased in DDQ-treated cells relative to untreated cells ( Fig. 4B and D) .
Mitochondrial biogenesis proteins PGC1a (P ¼ 0.01), Nrf1 (P ¼ 0.001), Nrf2 (P ¼ 0.01) and TFAM (P ¼ 0.01) levels were decreased in Ab-incubated cells relative to untreated cells. Interestingly, significant increase of mitochondrial biogenesis protein levels was observed in DDQ-treated cells relative to untreated cells ( Fig. 4B and D) .
Mitochondrial fission proteins Drp1 (P ¼ 0.01) and Fis1 (P ¼ 0.02) were reduced and fusion protein Mfn1 (P ¼ 0.04) was significantly increased in AbþDDQ-treated cells relative to untreated cells ( Fig. 4A and C) . Synaptic proteins, synaptophysin (P ¼ 0.01) and PSD95 (P ¼ 0.04) levels significantly increased in AbþDDQ-treated cells relative to untreated cells. Decreased levels of Drp1 (P ¼ 0.004) were found in DDQ þ Ab-treated cells relative to untreated cells ( Fig. 4A and C) . Overall, these findings suggest that DDQ reduces fission activity and enhances fusion activity in the presence of Ab.
Comparison with Ab-treated cells. As shown in Figure 4A and B, significantly reduced levels of fission protein, Drp1 were found in cells treated with AbþDDQ (Drp1, P ¼ 0.01) and DDQ þ Ab (Drp1, P ¼ 0.001; Fis1, P ¼ 0.04) relative to Ab-treated cells. In contrast, fusion proteins were increased in AbþDDQ (Mfn1, P ¼ 0.01; Mfn2, P ¼ 0.01) and DDQ þ Ab (Mfn1, P ¼ 0.02; Mfn2, P ¼ 0.01) treated cells relative to Ab-treated cells.
In AbþDDQ cells exhibited increased mitochondrial biogenesis protein levels (Nrf1 (P ¼ 0.04), Nrf2 (P ¼ 0.01) and TFAM (P ¼ 0.01) relative to Ab-treated cells. Similarly, DDQ pre-treated (DDQ þ Ab) cells showed significantly increased levels of mitochondrial biogenesis proteins (Nrf1 (P ¼ 0.01), Nrf2 (P ¼ 0.01) and TFAM (P ¼ 0.004) relative to Ab-treated cells ( Fig. 4B and D) .
Synaptic proteins were increased in AbþDDQ (synaptophysin, P ¼ 0.01; PSD95, P ¼ 0.03) and DDQ þ Ab (synaptophysin, P ¼ 0.04; PSD95, P ¼ 0.001) treated cells relative to Ab-treated cells ( Fig. 4A and C) , indicating that DDQ enhances synaptic activity in the presence of Ab in cells.
DDQ reduces Ab and Drp1 levels
To determine whether DDQ reduces Ab and Drp1 levels, we conducted immunoblotting analysis, in cells treated with DDQ, AbþDDQ and DDQ þ Ab. As shown in Figure 5A , we found reduced levels of 4 kDa Ab in cells treated AbþDDQ and DDQ þ Ab relative to cells treated with Ab alone. We also found reduced levels of Drp1 in cells treated DDQ, AbþDDQ and DDQ þ Ab relative to untreated and Ab-treated cells (Fig. 4A ).
Co-immunoprecipitation and immunoblotting analysis using DDQ-treated SHSY5Y cellsþAb
To determine whether DDQ reduces the interaction of Ab with Drp1 in Ab-incubated cells, we performed co-immunoprecipitation Figure 5B , we found reduced interaction between Ab and Drp1 in DDQ pre-treated, DDQ post-treated relative to Ab-incubated cells. Reduced interaction was strong in DDQ pre-treated than DDQ post-treated cells, indicating that prevention is better than treatment.
Co-immunoprecipitation and immunoblotting analysis of mutant APP Swe/Ind cells treated with DDQ
To determine whether DDQ reduces the interaction of Ab with Drp1 in mutant APP Swe/Ind cells, we used mutant APP Swe/Ind cDNA construct transfected into mouse neuroblastoma (N2a) cells and further cells were treated with DDQ. We performed immunoprecipitation with Ab (6E10) antibody and immunoblotting analysis with 6E10 and we also performed coimmunoprecipitation analysis with Ab (6E10) antibody and immunoblotting analysis with Drp1 antibody. As shown in Immunofluorescence analysis of Drp1, synaptophysin and PSD95
To determine the effect of Ab and DDQ on Drp1, synaptophysin and PSD95 levels and localizations, immunofluorescence analysis was performed in cells treated as shown in Figure 7 .
As shown in Figure 7A and B, we found significantly increased Drp1 (P ¼ 0.003) levels in Ab-treated cells relative to untreated cells, indicating that Ab enhances fission activity in cells. In contrast, decreased Drp1 levels were found in DDQtreated cells relative to untreated cells, but this was not significant. The synaptic protein synaptophysin (P ¼ 0.002) and PSD95 (P ¼ 0.001) were significantly reduced in Ab-treated cells relative to untreated cells ( Fig. 7A and B) .
Significantly reduced levels of fission protein Drp1 were found in cells treated with AbþDDQ (P ¼ 0.03) and DDQþ Ab (P ¼ 0.004) relative to Ab-treated cells (Fig. 7A and B) . In contrast, synaptic proteins were increased in AbþDDQ (synaptophysin, P ¼ 0.04; PSD95, P ¼ 0.03) and DDQ þ Ab (synaptophysin, P ¼ 0.004; PSD95, P ¼ 0.01) treated cells relative to Ab-treated cells (Fig. 7A and B) , indicating that DDQ enhances synaptic activity in the presence of Ab in cells. Overall, the immunofluorescence findings agreed with the immunoblotting results.
Double-labeling immunofluorescence analysis of Drp1 and Ab
To determine whether Drp1 localizes and interacts with Ab, we conducted double-labeling analysis of Drp1 and Ab in DDQ pretreated, post-treated and untreated, Ab-incubated cells. As shown in Figure 8 , the immunoreactivity of Drp1 was colocalized with Ab immunoreactivity (monomeric), indicating that Drp1 interacts with Ab.
Further, we found reduced co-localization of Drp1 with Ab in DDQ pre-treated and post-treated Ab-incubated cells relative to Ab-incubated cells alone. Drp1 and Ab colocalization is 
Transmission electron microscopy
To determine the effects of DDQ on mitochondrial number and morphology, and any rescual effects of DDQ on mitochondria in the untreated and Ab-treated cells, we used TEM on untreated, DDQ, Ab, AbþDDQ and DDQ þ Ab, treated SHSY5Y cells.
Mitochondrial number and length comparison of DDQ, Ab, abþDDQ and DDQþab-treated cells with untreated cells. Mitochondrial number: As shown in Figure 10 , we found significantly increased number of mitochondria in Ab-treated cells relative to untreated cells (P ¼ 0.03), suggesting that Ab treatment enhances mitochondrial number, in other words Ab treatment enhances mitochondrial fragmentation. On the other hand, DDQ treatment reduced the number of mitochondria relative to untreated cells (P ¼0.003), suggesting that DDQ treatment reduces mitochondrial fragmentation. Interestingly, AbþDDQ and DDQ þ Ab-treated cells have exhibited approximately equal number of mitochondria relative to untreated cells (Fig. 10) .
Mitochondrial length. We also measured mitochondrial length in order to understand whether DDQ treatment alters mitochondrial length. As shown in Figure 10 , we found mitochondrial length is significantly increased in cells treated with DDQ relative to untreated cells. On the contrary, mitochondrial length is significantly reduced in Ab-treated cells (P ¼ 0.005) relative to untreated cells. Mitochondrial length is not significantly changed in AbþDDQ and DDQ þ Ab-treated cells relative to untreated cells, indicating that DDQ preventing/rescuing mitochondrial length in the presence of Ab.
Mitochondrial number and length comparison of abþDDQ and DDQþab-treated cells with Ab-treated cells. The number of mitochondria were significantly reduced in DDQ-pre (P ¼ 0.001) and post-treated (P ¼ 0.02) cells relative to cells treated with Ab alone (Fig. 10) . Mitochondrial length is significantly increased in DDQpre (P ¼ 0.02) and post-treated (P ¼ 0.02) cells relative to cells treated with Ab alone. These findings indicate that DDQ reduces excessive mitochondrial fragmentation and increased mitochondrial length in AD neurons. 
Mitochondrial functional assays
H 2 O 2 production. As shown in Figure 11 , significantly increased levels of hydrogen peroxide (H 2 O 2 ) were found in mitochondria from cells incubated with Ab (P ¼ 0.001). In measurements taken of H 2 O 2 from mitochondria isolated from cells treated with DDQ, significantly decreased levels of H 2 O 2 (P ¼ 0.01) were found relative to untreated cells. These findings suggest that Ab increases free radical production and DDQ reduces H 2 O 2 in the presence of Ab. Significantly increased levels were found in cells incubated with AbþDDQ (P ¼ 0.01) and DDQ þ Ab (P ¼ 0.03) relative to untreated cells. When the data were compared between cells incubated with Ab and AbþDDQ (P ¼ 0.04) and DDQ þ Ab (P ¼ 0.002) cells, H 2 O 2 levels were significantly reduced, indicating that DDQ reduces H 2 O 2 levels in the presence of Ab (Fig. 11) .
Lipid peroxidation. Significantly increased levels of lipid peroxidation (4-hydroxy-nonenol) were found (P ¼ 0.002) in Ab-treated relative to untreated cells (Fig. 11) . However, significantly decreased levels were found in the DDQ-treated cells (P ¼ 0.04) relative to untreated cells. We also found significantly reduced levels of lipid peroxidation in AbþDDQ (P ¼ 0.04) and DDQ þ Ab (P ¼ 0.04) relative to cells incubated with Ab alone, indicating that DDQ reduces lipid peroxidation levels in the presence of Ab (Fig. 11) .
ATP production. As shown in Figure 11 , significantly decreased levels of ATP were found in cells that were incubated with Ab (P ¼ 0.01) relative to untreated cells. Significantly increased levels of ATP were found in cells treated with DDQ compared with untreated cells. Significantly increased levels were found in cells incubated with AbþDDQ (P ¼ 0.03) relative to untreated cells (Fig. 11) . Significantly increased ATP levels were found in AbþDDQ (P ¼ 0.04) and DDQ þ Ab-treated (P ¼ 0.01) cells relative to Ab-incubated cells, indicating DDQ increases ATP levels in the presence of Ab.
Cytochrome oxidase activity. Significantly decreased levels of cytochrome oxidase activity were found in cells that were incubated with Ab (P ¼ 0.04) (Fig. 11) . However, significantly increased levels of cytochrome oxidase activity were found in DDQ-treated cells relative to untreated cells. Cytochrome oxidase activity levels were unchanged in AbþDDQ and DDQ þ Ab cells relative to untreated cells. Similar to ATP levels, cytochrome oxidase activity levels were increased in AbþDDQ and DDQ þ Ab-treated (P ¼ 0.03) cells relative to Ab-incubated cells (Fig. 11) , indicating DDQ increases cytochrome oxidase activity levels in the presence of Ab.
GTPase-Drp1 activity. To determine whether Ab affects GTPase-Drp1 activity in cells that treated with Ab incubation, we measured GTPase-Drp1 activity from Drp1 IP elutes of all cell treatments. Interestingly, we also found significantly increased Drp1 enzymatic activity in Ab-treated cells (P ¼ 0.01) relative to untreated cells. We found decreased levels were found in the DDQ-treated cells (P ¼ 0.04) relative to untreated cells. Significantly increased Drp1 enzymatic activity was observed in cells incubated with AbþDDQ (P ¼ 0.04) relative to untreated cells. Drp1 enzymatic activity was reduced in cells treated like AbþDDQ (P ¼ 0.05) and DDQ þ Ab (P ¼ 0.02) relative to cells incubated with Ab, indicating that DDQ reduces GTPase-Drp1 activity in the presence of Ab (Fig. 11) .
Cell viability
Significantly decreased levels of cell viability were found in Abtreated cells (P ¼ 0.01) (Fig. 12) relative to untreated cells. Cell viability was also significantly increased in cells treated with DDQ (P ¼ 0.01) compared with untreated cells. Cell viability levels were unchanged in cells treated with AbþDDQ and DDQ þ Ab relative to untreated cells. Significantly increased cell viability levels were found in cells treated with DDQ þ Ab (P ¼ 0.03) relative to Ab-incubated cells, suggesting that DDQ increases cell viability in the presence of Ab.
Discussion
The purpose of our study was to identify a drug molecule that can reduce Drp1 and Ab levels and also to inhibit abnormal interaction between Drp1 and Ab that reduce excessive mitochondrial fragmentation and maintain mitochondrial function and synaptic activity in AD neurons. The elevated levels of Ab and increased expressions of mitochondrial fission protein Drp1, and abnormal interactions between Ab and Drp1, have been found to induce synaptic dysfunction and mitochondrial damage, causing neuronal dysfunction in AD neurons. As our target to develop aqua-soluble drug molecule, that is capable of reducing Ab and Drp1 levels in AD neurons and also that can inhibit Ab and Drp1 interaction, we have designed 82 molecular crystal structures based on existing drug molecules and screened by molecular docking studies. We designed these molecules with multiple functions including anti-inflammatory, anti-antioxidant, pro-longevity, and anti-amyloid functions. For the first time, we selected DDQ as a novel drug target because, it bound at Ab and Drp1 interacting sites to inhibit Ab and Drp1 complex formation and also showed better docking score than other designed molecules and existing molecules such as MitoQ, Mdivi1 and SS31. Additionally, DDQ is formulated to dissolve in water. DDQ is obstructing Ab and Drp1 binding sites by direct interactions at active sites of Ab (ser8 and Leu34) and Drp1 (ASN16 and Glu16) (Fig. 1) . DDQ is readily bound with Drp1 (independently before forming a Drp1-Ab complex), leaving less Drp1 binding sites with Ab -meaning DDQ interfere with Drp1 and Ab interactions.
We examined the protective effects of DDQ in healthy human neuroblastoma cells, and also in neurons incubated with Ab42. We studied preventive (DDQ þ Ab) and intervention (AbþDDQ) effects of DDQ against Ab in AD neurons. We measured mRNA and protein levels of mitochondrial dynamics, biogenesis and synaptic genes using real time RT-PCR, immunoblotting and immunofluorescence analysis. We also assessed mitochondrial function by measuring H 2 O 2 , lipid peroxidation, cytochrome oxidase activity, GTPase-Drp1 activity and mitochondrial ATP. Further, we studied cell viability using the MTT assay. Mitochondrial number and morphology was studied using transmission electron microscopy.
Mitochondrial fission protein levels were increased and fusion, biogenesis and synaptic protein levels were decreased in Ab-treated neurons relative to untreated neurons, indicating the toxicity of Ab. On the contrary, DDQ enhanced fusion activity; reduced fission machinery; and increased mitochondrial biogenesis and synaptic activities. DDQ pre-and post-treated of Ab-incubated cells showed appropriate mitochondrial dynamics and synaptic activities similar to untreated neurons. Likewise, DDQ pre-and post-treated of Ab-incubated neurons showed reduced abnormal mitochondrial dysfunction, maintained cell viability and synaptic activity, relative to Ab-treated neurons. Further, the protective effects of DDQ were stronger in pretreated neurons than in post-treated neurons -in other words, DDQ works better in prevention than treatment in ADlike neurons. Mitochondrial count is significantly decreased in DDQ-treated neurons relative to untreated neurons. These findings strongly suggest that DDQ is a promising molecule to treat AD neurons.
DDQ reduces the levels of Ab and Drp1 and interaction between Ab and Drp1
Using co-immunoprecipitation, immunoblotting and doublelabeling immunofluorescence analyses, we studied Drp1 and Ab and their interactions. We found that Ab interacts with Drp1 in Ab-incubated cells, and this interaction is gradually reduced by pre-and post-treatment of DDQ and the reduction of Drp1 and Ab is stronger in DDQ pre-treated cells than post-treated. Further, we also found reduced levels of Ab and Drp1 in DDQtreated AD (AbþDDQ and DDQ þ Ab) neurons (Fig. 5) .
Using co-immunoprecipitation and immunoblotting analysis and mutant APP Swe/Ind cells, we also studied Drp1 and fulllength APP and Ab levels, and also Drp1 interaction with Ab. We found reduced levels of Drp1, full-length APP and Ab in DDQtreated mutant APP Swe/Ind cells relative to DDQ untreated APP Swe/Ind cells, indicating that DDQ reduces Drp1, full-length APP and Ab levels in mutant APP Swe/Ind cells (Fig. 6) .
Our double-labeling immunofluorescence analysis (Fig. 8 .) strongly agreed with our co-IP data. Our previous findings states that these interaction/colocalization increases as AD progresses (10) . Our double-labeling immunofluorescence analysis of Ab and Drp1 in DDQ pre-treated and post-treated in the presence Ab showed reduced Ab and Drp1 colocalization relative to neurons incubated with Ab alone.
The reduced interaction between Ab and Drp1 may be due to the reduced synthesis/production of Ab and Drp1 in DDQ preand post-treated cells. This reduced interaction of Ab with Drp1 in DDQ pre-and post-treated cells may reduce mitochondrial fragmentation and keep the mitochondria in normal count, normal length and normal function and further it may protect to neuronal cells from Ab attack. These findings lead to the conclusion that DDQ reduced Ab and Drp1 levels and also prevented/ recused the interaction of Ab and Drp1; and inhibit mitochondrial fragmentation in neurons affected by AD. Our current findings of Figure 5 (SHSY5Y cells pre-and post-treated DDQ and Ab) and Figure 6 (mutant APP Swe/Ind cells treated with DDQ) strongly suggest that DDQ reduces the synthesis/production of full-length APP, Ab and Drp1 and these reduced levels of fulllength APP, Ab and Drp1 are one of the possible reasons for reduced interaction between Ab and Drp1 in AD neurons. Further, as expected DDQ is obstructing Ab and Drp1 binding sites by direct interactions at active sites of Ab (ser8 and Leu34) and Drp1 (ASN16 and Glu16) (Fig. 1) . DDQ is readily bound with Drp1 (independently before forming a Drp1-Ab complex), leaving less Drp1 binding sites with Ab. However, additional research is needed to determine the precise effects of DDQ's role in reducing physical interaction between Ab and Drp1.
DDQ reduces Ab42 in mutant APP Swe/ind cells
To determine whether DDQ reduces Ab42 levels, we measured both Ab42 and Ab40 in mutant APP Swe/Ind cells treated and untreated with DDQ. Interestingly, Ab42 levels were significantly reduced and Ab40 levels were significantly increased in DDQ-treated mutant APP Swe/Ind cells (Fig. 9) relative to DDQuntreated APP Swe/Ind cells. These observations are interesting and may have therapeutic value for AD. It is possible that DDQ blocks/reduces the activity of the epsilon cleavage site (that is responsible for Ab42 production) at C-terminal region of Ab in mutant APP Swe/Ind cells. Additional research is still needed in order to determine how DDQ reduces the levels of Ab42 and increases Ab40 levels in AD neurons.
DDQ maintains mitochondrial function and cell viability
To determine differences in mitochondrial function among DDQ-treated and -untreated cells (as shown in our strategy Fig. 3) , we assessed mitochondrial function assays in all treated and untreated cells. The parameters included H 2 O 2 production, lipid peroxidation, ATP production, GTPase Drp1 enzymatic activity and cell viability. In Ab-treated cells, mitochondrial function was found to be defective and cell viability was also reduced. Our observations agree with others on Ab induced defective mitochondrial function and cell viability. Interestingly, DDQ-treated cells showed enhanced mitochondrial function (Fig. 11 ) and increased cell viability (Fig. 12) , implying that DDQ-treated cells exhibited increased mitochondrial ATP, cytochrome oxidase activity and cell viability, and reduced free radicals and oxidative stress. These observations strongly suggest that DDQ reduces cellular toxicity and boosts mitochondrial function and promotes cell longevity. In summary, for the first time, we designed and synthesized DDQ based on the best docking score and its binding interactions with Ab and Drp1 complex. In AD neurons treated with DDQ, we found reduced levels of mitochondrial fission gene expressions and proteins, and increased levels of mitochondrial fusion, biogenesis and synaptic gene expressions and proteins relative to neurons incubated with Ab alone indicating that DDQ is protective against Ab-and Drp1-induced toxicities. Hence, it is proved that DDQ has protective effects on neuronal cells and it protects against Ab induced mitochondrial and synaptic toxicities in AD neurons. Further, it is required to do more preclinical using AD mouse models and clinical studies using AD patients treated with DDQ to determine it's the preventive effects against Ab induced neuronal toxicities in AD affected animal and human models.
Materials and Methods
Chemicals and reagents
Chemicals for synthesis of DDQ were procured from SigmaAldrich and Merck and used as such, without further purification. All solvents used for spectroscopic and other physical studies were reagent grade and were further purified by literature methods. Infrared spectra (IR) were obtained on a PerkinElmer Model 281-B spectrophotometer. Samples were analyzed as potassium bromide disks. Absorptions were reported in wave numbers (cm À1 
Molecular docking
In preliminary studies, molecular docking simulations were generated and prepared, using MOE software. The crystal structures of Ab (PDB ID: 1ba4) and dynamin-1-like protein (PDB ID: 4h1u) were retrieved from the Protein Data Bank. PDB structure of Drp1 was loaded into the MOE working environment, ignoring all heteroatoms and water molecules. When receptor was loaded into the MOE molecular modeling software, the heteroatoms and water molecules were removed, and polar hydrogens were added to relieve any close contact between the X and Y axis. Protonation of the 3D structure was carried out for all of the atoms, in the implicit solvated environment at 300 K that had a pH of 7 and a salt concentration of 0.1. Electrostatic potential was applied to a cut-off value of 1.5 Å at a dielectric value of 1. A non-bonded cut-off value of 8 Å was applied to the Leonard-Jones terms. After protonation, the completed structure was energy-minimized, using the MMFF94x force field at a gradient cut off value of 0.05. Molecular dynamic simulations were carried out at a constant temperature of 300 K for a heat time of 10 picoseconds. All simulations were carried out, over a total of 2000 picoseconds. The time step was considered 0.001, and the temperature relaxation time was set to 0.2 picoseconds. The position, velocity, and acceleration were determined and the data collected and saved every 0.5 picoseconds.
PDB structure of Ab was constructed in the MOE working environment and subjected to energy minimization. MMFF94x force fields were included, and the related potential energy terms were enabled for all bonded interactions, Van der Waals interactions, and electrostatic interactions and restraints. The non-bonded cutoff value was enabled between 8-10 Å . A generalized born implicit salvation model was enabled, all parameters were fixed, the gradient was set to 0.05, and the partial charges of the force field were enabled in order to run calculations during the minimization process. Dynamic simulations were carried out, using the NosePoincare-Anderson equational algorithm. Consequently, we formed Ab and Drp1 complex, which further used as receptor to find the binding interactions designed molecules.
The 3D structures of all designed structures were constructed in the MOE working environment and subjected to energy minimization. MMFF94x force fields were included, and the related potential energy terms were enabled for all bonded interactions, Van der Waals interactions, and electrostatic interactions and restraints. The non-bonded cut-off value was enabled between 8 and 10 Å . A generalized Born implicit salvation model was enabled, all parameters were fixed, the gradient was set to 0.05, and the partial charges of the force field were enabled in order to run calculations during the minimization process. Dynamic simulations were carried out, using the NosePoincare-Anderson equational algorithm. The temperature for the proteins was set to 30 K and was increased to 300 K for runtime temperature. Heat time and cool time were set to 0 picoseconds. The site for the Prediction of Binding Site for Ligand Activity of the crystallographic structure of Drp1 was defined. The MOE dock module was used to dock the compounds into specified binding sites along with the reference compound exemestane. Exemestane was found in contact with 3S7S, determined by alpha PMI (Principle Moments of Inertia) placement methodology, where Poses were generated by aligning principal moments of inertia and ligand conformations to a randomly generated subset of alpha spheres in the receptor site. Thirty docked conformations were generated for each ligand and ranked by an alpha HB scoring function, which is a linear combination of the geometric fit of the ligand to the binding site and hydrogen bonding effects. From all the receptor-ligand complexes, the conformation with the lowest docking score was chosen for additional analysis.
In vitro biological studies of DDQ DDQ exhibited a good molecular docking score and better binding interactions compared to the other molecules those we developed. Therefore, we decided to quantify the biological effects of DDQ in AD pathogenesis. Therefore, we treated AD neurons with DDQ and quantified the effect of DDQ on gene expression levels of synaptic, AD-related, and mitochondrial-related genes. For these treatments, we performed the following protocols: We treated SHSY5Y cells in five different groups as explained in Figure 3 . Figure 3 illustrates the experimental strategy of our cell culture work and including treatments. The cells were grown in a medium (1:1 DMEM and F12, 10% FBS, 1x penicillin, and streptomycin) at 37 C in a humified incubator with a 5% Quantification of mitochondrial dynamics, biogenesis and synaptic genes expression using real-time RT-PCR Using the reagent TriZol (Invitrogen), we isolated total RNA from control and experimental groups (Fig. 3) . Using primer express Software (Applied Biosystems), we designed the oligonucleotide primers for the housekeeping genes b-actin, mitochondrial structural genes; fission (Drp1 and Fis1); fusion genes (MFN1, MFN2); mitochondrial biogenesis genes PGC1a, Nrf1, Nrf2 and TFAM; and synaptic genes (PSD95, synaptophysin, synapsin 1, synapsin 2, synaptobrevin 1, synaptobrevin 2, synaptopodin, and GAP43). The primer sequences and amplicon sizes are listed in Table 3 . Using SYBR-Green chemistry-based quantitative realtime RT-PCR, we measured mRNA expression of the genes mentioned above as described by Manczak et al. (10) .
Immunoblotting analysis
To determine whether DDQ, or Ab alters the protein levels of mitochondrial and synaptic genes that showed altered mRNA expressions in our real-time RT-PCR, we performed immunoblotting analyses of protein lysates from cells of control and experimental treatments in independent cells treatments (n ¼ 3) as described in Manczak et al. (13) . Details of proteins, dilutions of antibodies used for immunoblotting analysis was given in Table 4 Mutant APP Swe/Ind cells: We purchased mutant APP Swe cDNA clone (pCAX-APP Swe/Ind ) from Addgene -https://www.addgene.org and verified expression of mutant APP APP Swe/Ind cDNA and further sub-cloned into a mammalian expression vector (Arubala P. Reddy -unpublished observations). We transfected mutant APP Swe/Ind cDNA into mouse neuroblastoma (N2a) cells for 24 h and after transfection, cells were treated with DDQ (250nM) for 24 h. We harvested mutant APP Swe/Ind cells treated and untreated with DDQ and prepared protein lysates and performed coimmunoprecipitation using Ab (6E10) antibody and conducted immunoblotting analysis with 6E10 and Drp1 antibodies.
We performed co-immunoprecipitation (co-IP) assays using the Dynabeads Kit for Immunoprecipitation (Invitrogen). Briefly, 50 mL of Dynabeads containing protein G was incubated with 10 mg 6E10 or 10 lg of the Drp1 antibodies (both mono-and polyclonal antibodies; Santa Cruz), with rotation, for 1 h at room temperature. We used all the reagents and buffers provided in the kit. Details of antibodies used for co-IP and western blotting are given Table 5 . The Dynabeads-Ab complex was washed three times with a washing buffer and was then incubated overnight with 400 lg of protein at 4 C, with rotation. The incubated Dynabead antigen/antibody complexes were washed again 3 times with a washing buffer, and an immunoprecipitant was eluted from the Dynabeads, using a NuPAGE LDS sample buffer. The Ab and Drp1 IP elute was loaded onto a 10-20% gradient gel, followed by western blot analysis of Ab and/or Drp1 antibodies. We also cross-checked the results by performing co-IP experiments, using both anti-Ab and anti-Drp1 antibodies (10).
Immunofluorescence analysis
To study immune-reactivity of proteins of interest, cells were grown on coverslips using regular cell culture medium and treated as shown in strategy Figure 3 and performed immunofluorescence analysis using the antibodies in these treated and untreated cells as described by Manzcak et al. (13) . Details of proteins, dilutions of antibodies used for immunofluorescence analysis are given in Table 6 . Cells were washed with warm PBS, fixed in freshly prepared 4% paraformaldehyde in PBS for 10 min, and then washed with PBS and permeabilized with 0.1% Triton-X100 in PBS. They were blocked with 1% blocking solution (Invitrogen) for 1 h at room temperature. All neurons were incubated overnight with primary antibodies. The neurons were incubated with appropriate secondary antibodies. The cells were washed 3 times with PBS, and slides were mounted. Photographs were taken with a multiphoton laser scanning microscope system (ZeissMeta LSM510). To quantify the immunoreactivity of proteins of interest, for each treatment 10-15 photographs were taken at Â20 magnification.
Double labeling immunofluorescence analysis of Drp1 and Ab
To determine the interaction between Drp1 and Ab, we conducted double-labeling immunofluorescence analysis, using an anti-Drp1antibody (rabbit polyclonal, Santa Cruz Biotechnology) and 6E10 (Covance). As described earlier, the sections were deparaffinized and treated with sodium borohydrate to reduce autofluorescence. For the first labeling, the Ab-incubated (DDQ pre-treated, post-treated and untreated) cells were incubated overnight with the anti-Drp1 antibody (1:200) at room temperature. On the day after this primary antibody incubation, the sections were washed with 0.05% Triton in PBS. They were then incubated with a secondary biotinylated anti-rabbit antibody at a 1:400 dilution (Vector Laboratories, Burlingame, CA, USA) or a secondary biotinylated anti-mouse antibody (1:400) for 1 h at room temperature. They were incubated for 1 h with labeled streptavidin, an HRP solution (Molecular Probes). The cells were washed three times each with PBS for 10 min, at pH 7.4, and treated with Tyramide Alexa488 for 10 min at room temperature.
For the second labeling, the cells were blocked for 1 h with a blocking solution containing 0.05% Triton in PBS þ 10% donkey serum þ 1% BSA. Then, they were incubated overnight with 6E10 (1:200 dilution, Covance) at room temperature. Next, they were incubated with the donkey anti-mouse secondary antibody labeled with Alexa 594 for 1 h at room temperature. They were cover-slipped with Prolong Gold and photographed with a confocal microscope (10) .
Transmission electron microscopy
To determine the effects of DDQ on the numbers of mitochondria and any rescue effects of DDQ on mitochondria in the mutant SHSY5Y neurons, we used TEM on untreated and treated SHSY5Y cells (as shown in Fig. 3) . [Batches 1-5]. All SHSY5Y cell 
Statistical analyses
Statistical analyses were conducted in two ways: 1. untreated cells versus cells treated with Ab, DDQ, DDQ þ Ab and AbþDDQ and 2. Cells treated with Ab versus DDQ þ Ab and AbþDDQ for mRNA and protein levels, cell viability and mitochondrial functional parameters H 2 O 2 , cytochrome oxidase activity, lipid peroxidation, ATP production and cell viability using appropriate statistical analysis. 
